. 2014 Nov 18;19(11):19021–19035. doi: 10.3390/molecules191119021

Table 2.

Antiproliferative activity against cancer cell lines of A549 and HCT116, and cytotoxicity against normal mice fibroblast BALB/3T3.

Compound	BALB/3T3 ^a IC₅₀ (μM)	A549 ^b IC₅₀ (μM)	HCT116 ^c IC₅₀ (μM)
cisplatin	9.498 ± 0.500	8.965 ± 3.333	9.465 ± 1.300
7b	6.423 ± 0.996	4.555 ± 2.086	0.893 ± 0.397
7d	4.953 ± 0.220	3.663 ± 0.535	1.756 ± 0.329
7e	5.945 ± 1.163	5.060 ± 0.911	2.206 ± 0.687
7f	4.914 ± 0.430	4.444 ± 0.685	0.832 ± 0.216
8	2.725 ± 0.731	1.328 ± 0.586	0.557 ± 0.085
4d	0.768 ± 0.155	0.649 ± 0.080	0.130 ± 0.014
6 ^d	1.047 ± 0.127	0.172 ± 0.052	0.258 ± 0.107
DHA (2)	-	>20 ^e	1.34 ± 1.06 ^e

^a BALB/3T3, mouse embryonic fibroblast cell line; ^b A549, human non-small-cell lung adenocarcinoma cell line; ^c HCT116, human colon cancer cell line; ^d Activities against BALB/3T3, A549, and HCT116 of the compound 9 derived from 6 and artesunate 3 are cited in Reference [54]; ^e Reference [53].